Inclusion criteria :

          -  Histologically- or cytologically-confirmed diagnosis of advanced or metastatic NSQ
             NSCLC with no EGFR sensitizing mutation or BRAF mutation or ALK/ROS alterations.

          -  No prior systemic chemotherapy for the treatment of the participant's advanced or
             metastatic disease (treatment with chemotherapy and/or radiation as part of
             neoadjuvant/adjuvant therapy is allowed as long as completed at least 6 months prior
             to diagnosis of advanced or metastatic disease).

          -  Expression of CEACAM5 as demonstrated prospectively by a centrally assessed
             Immunohistochemistry (IHC) assay of ≥2+ in intensity involving at least 50% of the
             tumor cell population in archival tumor sample (or if not available fresh biopsy
             sample).

          -  Measurable disease based on RECIST 1.1.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Contraceptive use by men or women should be consistent with local regulations
             regarding the methods of contraception for those participating in clinical studies

          -  Capable of giving signed informed consent

        Exclusion criteria:

          -  Medical condition requiring concomitant administration of a medication with a narrow
             therapeutic window and metabolized by CYP450 or a strong CTP3A inhibitor.

          -  Uncontrolled brain metastases and history of leptomeningeal disease.

          -  Significant concomitant illness, including any severe medical condition that, in the
             opinion of the investigator or Sponsor, would impair the patient's participation in
             the study or interpretation of the results.

          -  History within the last 3 years of an invasive malignancy other than the one treated
             in this study, with the exception of resected/ablated basal or squamous-cell carcinoma
             of the skin or carcinoma in situ of the cervix, or other local tumors considered cured
             by local treatment.

          -  History of known acquired immunodeficiency syndrome (AIDS) related illnesses or known
             HIV disease requiring antiretroviral treatment, or active hepatitis A, B, or C
             infection.

          -  History of active autoimmune disease that has required systemic treatment in the past
             2 years.

          -  History of allogeneic tissue/solid organ transplantation.

          -  Active infection requiring IV systemic therapy within 2 weeks prior to randomization
             or active tuberculosis.

          -  Interstitial lung disease or history of pneumonitis that has required oral or IV
             steroids

          -  Non-resolution of any prior treatment-related toxicity to < Grade 2 according to NCI
             CTCAE V5.0, with the exception of alopecia, vitiligo, or active thyroiditis controlled
             with hormone replacement therapy.

          -  Unresolved corneal disorder or any previous corneal disorder considered by an
             ophthalmologist to predict higher risk of drug-induced keratopathy. The use of contact
             lenses is not permitted.

          -  Symptomatic herpes zoster within 3 months prior to screening.

          -  Significant allergies to humanized monoclonal antibodies.

          -  Clinically significant multiple or severe drug allergies, intolerance to topical
             corticosteroids, or severe post-treatment hypersensitivity reactions (including, but
             not limited to, erythema multiforme major, linear immunoglobulin A [IgA] dermatosis,
             toxic epidermal necrolysis, and exfoliative dermatitis).

          -  Concurrent treatment with any other anticancer therapy.

          -  Have received prior chemotherapy treatment for advanced/metastatic NSCLC.

          -  The patient is a candidate for a curative treatment with either surgical resection
             and/or chemoradiation

          -  Washout period before the first administration of study intervention of less than 3
             weeks or less than 5 times the half-life, whichever is shorter, for any
             investigational treatment).

          -  Any prior therapy targeting CEACAM5.

          -  Any prior treatment with any other anti-PD-1, or PD-L1 or programmed death ligand 2
             (PD-L2), anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4.

          -  Any prior maytansinoid treatment (DM1 or DM4 ADC).

          -  Is receiving systemic steroid therapy ≤3 days prior to the first dose of study therapy
             or receiving any other form of immunosuppressive medication. Daily steroid replacement
             therapy or any corticosteroid premedication if applicable are allowed.

          -  Any radiation therapy to lung >30 Gy within 6 months of first study intervention
             administration.

          -  Has received or will receive a live vaccine within 30 days prior to the first study
             intervention administration.

          -  Any major surgery within the preceding 3 weeks of the first study intervention
             administration.

        Prior/concurrent clinical study experience

          -  Current participation in any other clinical study involving an investigational study
             treatment or any other type of medical research.

          -  Poor organ function

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.